Investor Presentaiton
Outcome model demonstrates that Shield
has the highest averted rate of CRC deaths
Lifetime Colonoscopies & CRC Deaths Averted
Real-world longitudinal adherence model for simulated cohort
Model parameters
INVESTOR 20
DAY 23
CRC death averted per 1,000 individuals
16
14
12
10
10
8
6
4
2
FIT
0
0
500
Shield
mts DNA
1000
1500
Colonoscopy
Colonoscopies per 1,000 individuals
Screening
Interval1-3
CRC
Sensitivity2,3
Specificity2,3
One-Time
Adherence 3-6
Colonoscopy
10 years
95%
86%
38%
FIT
1 year
74%
96%
43%
mtsDNA
3 years
92%
90%
65%
shield™
3 years
83%
90%
90%
2000
2500
1. Knudsen AB et al. "Colorectal Cancer Screening: An Updated Decision Analysis." USPSTF [Internet]. 2021. 2. Knudsen AB et al.. Estimation of benefits, burden, and harms of colorectal cancer
GUARDANT screening strategies: modeling study for the US Preventative Services Task Force. Jama. 2016 Jun 21;315(23):2595-609. 3. Guardant Health Internal Data. 4. Singal AG et al. "Effect of Coloscopy
Outreach vs Fecal Immunochemical Test Outreach on Colorectal Cancer Screening Completion: A Randomized Clinical Trial." JAMA 318, no. 9 (05 2017): 806-15. 5. J.P. Morgan Healthcare Conference
2018. 6. Akram A et al. "Replacing the Guaiac Fecal Occult Blood Test With the Fecal Immunochemical Test Increases Proportion of Individuals Screened in a Large Healthcare Setting." Clinical
Gastroenterology and Hepatology 15 no 8 (August 2017): 1265-1270 e1
111View entire presentation